A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs LMB 100 (Primary) ; SEL-403 (Primary) ; Sirolimus (Primary)
- Indications Mesothelioma; Peritoneal cancer
- Focus Adverse reactions
- 31 Dec 2018 Status changed from recruiting to suspended as Grand 5 pneumonits occurred. as Per PI and FDA enrollment is hold.
- 08 Sep 2018 Planned number of patients changed from 20 to 23.
- 13 Mar 2018 Planned number of patients changed from 40 to 20.